Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
by
Meis, Jacques F.
, Rhodes, Johanna L.
, Chowdhary, Anuradha
, Verweij, Paul E.
, Fisher, Matthew C.
in
Antifungal Agents - pharmacology
/ Aspergillosis - drug therapy
/ Aspergillosis - veterinary
/ Aspergillus fumigatus - drug effects
/ Aspergillus fumigatus - genetics
/ Aspergillus fumigatus - physiology
/ Azole Resistance
/ Azoles - pharmacology
/ Drug Resistance, Fungal
/ Epidemiology
/ Fungicides
/ Fungicides, Industrial - pharmacology
/ Phenotype
/ Review
/ Treatment
/ Worldwide Emergence
2016
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
by
Meis, Jacques F.
, Rhodes, Johanna L.
, Chowdhary, Anuradha
, Verweij, Paul E.
, Fisher, Matthew C.
in
Antifungal Agents - pharmacology
/ Aspergillosis - drug therapy
/ Aspergillosis - veterinary
/ Aspergillus fumigatus - drug effects
/ Aspergillus fumigatus - genetics
/ Aspergillus fumigatus - physiology
/ Azole Resistance
/ Azoles - pharmacology
/ Drug Resistance, Fungal
/ Epidemiology
/ Fungicides
/ Fungicides, Industrial - pharmacology
/ Phenotype
/ Review
/ Treatment
/ Worldwide Emergence
2016
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
by
Meis, Jacques F.
, Rhodes, Johanna L.
, Chowdhary, Anuradha
, Verweij, Paul E.
, Fisher, Matthew C.
in
Antifungal Agents - pharmacology
/ Aspergillosis - drug therapy
/ Aspergillosis - veterinary
/ Aspergillus fumigatus - drug effects
/ Aspergillus fumigatus - genetics
/ Aspergillus fumigatus - physiology
/ Azole Resistance
/ Azoles - pharmacology
/ Drug Resistance, Fungal
/ Epidemiology
/ Fungicides
/ Fungicides, Industrial - pharmacology
/ Phenotype
/ Review
/ Treatment
/ Worldwide Emergence
2016
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
Journal Article
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
2016
Request Book From Autostore
and Choose the Collection Method
Overview
Aspergillus fungi are the cause of an array of diseases affecting humans, animals and plants. The triazole antifungal agents itraconazole, voriconazole, isavuconazole and posaconazole are treatment options against diseases caused by Aspergillus. However, resistance to azoles has recently emerged as a new therapeutic challenge in six continents. Although de novo azole resistance occurs occasionally in patients during azole therapy, the main burden is the aquisition of resistance through the environment. In this setting, the evolution of resistance is attributed to the widespread use of azole-based fungicides. Although ubiquitously distributed, A. fumigatus is not a phytopathogen. However, agricultural fungicides deployed against plant pathogenic moulds such as Fusarium, Mycospaerella and A. flavus also show activity against A. fumigatus in the environment and exposure of non-target fungi is inevitable. Further, similarity in molecule structure between azole fungicides and antifungal drugs results in cross-resistance of A. fumigatus to medical azoles. Clinical studies have shown that two-thirds of patients with azole-resistant infections had no previous history of azole therapy and high mortality rates between 50% and 100% are reported in azole-resistant invasive aspergillosis. The resistance phenotype is associated with key mutations in the cyp51A gene, including TR34/L98H, TR53 and TR46/Y121F/T289A resistance mechanisms. Early detection of resistance is of paramount importance and if demonstrated, either with susceptibility testing or through molecular analysis, azole monotherapy should be avoided. Liposomal amphotericin B or a combination of voriconazole and an echinocandin are recomended for azole-resistant aspergillosis.
This article is part of the themed issue ‘Tackling emerging fungal threats to animal health, food security and ecosystem resilience’.
Publisher
The Royal Society
MBRLCatalogueRelatedBooks
Related Items
Related Items
This website uses cookies to ensure you get the best experience on our website.